Designed and built with care, filled with creative elements

Follow Us

Top

Board of Governance

  /    /  Board of Governance

BOARD OF GOVERNANCE


The Board of Governance is a key group of Consortium and independent representatives that drive the VCB strategically. The independent members bring a range of expertise to the Board in fields of business strategy, scientific research, consumer relations and academia, to name a few.

Associate Professor Stella Clark, Advisory Committee Chair

Stella runs own business Stella Connect P/L, helping people, organisations and their ideas connect to maximise productive outcomes. Previously she was CEO of Obesity Australia and for nine years before that was CEO of the Bio21 Cluster (now Biomedical Research Victoria). This was preceded by senior management roles at the School of Graduate Studies, University of Melbourne and the Baker Heart Research Institute.

After gaining a PhD from the University of Melbourne in 1984, Stella spent three years as a CJ Martin Fellow at the Imperial Cancer Research Fund in London before returning to a research career in Australia. Her career was as a biomedical research scientist in the area of diabetes was recognised in 2014 when she was listed on the NHMRC website “High Achievers in Australian Health and Medical Research”. In 1994, Stella helped establish the Premier’s Award for Medical Research in Victoria, which recognises outstanding talent amongst young Victorian medical researchers.

Stella is currently Chair of the Victorian Cancer Biobank and is on the Boards of The Bionics Institute, the Melbourne Boston Sister City Association (where she Chairs the Hugh Rogers Fellowship Committee) and the ARC Centre of Excellence for Integrative Brain Function. In 2012 Stella was made an Honorary Principal Fellow at the University of Melbourne In 2013 she was awarded a Certificate of Merit upon graduation from the AICD Company Director’s Course.

Associate Professor Paul Field, Deputy Chair

Paul Field is an independent member of the VCB Governing Board bringing a deep background in biotechnology business development. He is currently the Senior Advisor – Life Sciences at Austrade, the Australian Government’s trade and investment promotion agency. His responsibility is the facilitation of foreign direct investment (FDI) into Australian life sciences. Before joining Austrade in September 2014, Paul was the Executive Chairman of Bio-Link, a privately-owned biotechnology business development company with offices in Melbourne and Sydney.

His work at Bio-Link involved the commercialisation of pre-clinical discovery programs in oncology, neurology, infectious diseases and other therapeutic areas. Before joining Bio-Link, he managed the biotech start-up company incubator at the Australian Technology Park, Redfern. Earlier he was commercialisation manager at the University of Technology, Sydney (UTS) focused on the translation of UTS life science research. Previously, he managed international sales for Cellabs Diagnostics, including a four year posting in Munich, Germany to establish a European distribution network for the Cellabs range of monoclonal antibodies and diagnostic tests.

Paul has served as an independent, non-executive director on a number of different Boards around Australia. His recent company directorships include the Co-operative Research Centre for Living with Autism Spectrum Disorders (Autism CRC Ltd.) headquartered at the University of Queensland and the ANZ Breast Cancer Trials Group Ltd. based in Newcastle, NSW. He is currently a Member of the Foundation Committee for the Global Health Alliance Melbourne.

VOTING CONSORTIUM MEMBERS

Dr. Beena Kumar, Assistant

Beena Kumar is the Director of Anatomical Pathology at Monash Health, Victoria, Australia. She has keen interest in breast and haematolymphoid pathology and is the designated pathologist for Monash Breast Screen and the Lymphoma Working Group at Monash Medical Centre.

She is also part of the faculty at Monash University, Melbourne, Australia and is involved in teaching undergraduate and post graduate medical students.
She is involved in medical research and has worked as a post-doctoral fellow at the Walter and Eliza Hall Institute of Medical Research and the Department of Pathology, University of Melbourne. She is currently involved in oncology based research projects in the areas of breast cancer, pancreatic cancer, lung cancer and lymphoid neoplasms. She has 52 publications in peer reviewed journals.

She is a member of the Immunohistochemistry Committee and serves as the Convenor for the Immunohistochemistry Module of the RCPA Anatomical Pathology Quality Assurance Programs Pvt Ltd. She is the Principal Investigator of the Monash Health Biobank and the Victorian Cancer Biobank branch operating at Monash Health.

Professor Christopher Gilfillan, Teacher

Professor Chris Gilfillan is currently Director of Endocrinology at Eastern Health and has a private endocrine practice in Box Hill. He oversees an active clinical research program and is currently principle or associate investigator in 9 international clinical trials. He has clinical interests in all aspects of endocrinology and research interests in type 2 diabetes, gestational diabetes, osteoporosis and metabolic bone disease and thyroid cancer. He is a Clinical Professor in the Monash Department of Medicine and the Eastern Clinical School and involved in the teaching of medical students, and basic physician trainees in endocrinology and internal medicine.

He was awarded a Centenary Medal for services to diabetes on the Mornington Peninsula.

He is currently principal investigator in a clinical trial of the effectiveness of wearable activity and blood glucose monitors in modifying health-related behaviour in type 2 diabetes. He has been involved in numerous clinical trial protocols testing novel therapies of type 2 diabetes and well as novel lipid lowering medications and new treatments for osteoporosis. He is also currently lead investigator in a study examining the genetic pathology of thyroid tumours and the isolation of thyroid cancer cells in peripheral blood. He is supervising a PhD student examining muscle mass and function in hip fracture patients and examining the molecular mechanisms of muscle wasting and sarcopenia in these patients.

Professor Stephen Fox, Principal

Professor Stephen Fox: Head, Molecular Pathology Laboratory, is also currently Director of Pathology at Peter Mac and Professorial Fellow in the Department of Pathology, The University of Melbourne. He took an Honours Degree and Medical Degree at the University of Bristol, UK (1986), before completing Pathology training in Oxford, UK after which he was awarded a Fellowship of the Royal College of Pathologists, UK, by examination, on first attempt in 1994. He was awarded a DPhil in Medicine at the University of Oxford in 1996 for work in angiogenesis and human cancer. He moved to Christchurch, New Zealand in 1996 as a Specialist Anatomical Pathologist and Senior Lecturer at the University of Otago and established the de novo and angiogenesis research laboratory. He returned to Oxford in 2001 as Clinical Reader in Pathology as part of the CRUK Chemopathology Group, while still coordinating the Christchurch laboratory. In February 2006 he moved to Melbourne, passed the Fellowship of the Royal College of Australasia by examination on first attempt and has recently been awarded a Fellowship in the Faculty of Science in the RCPA.

He has numerous positions of responsibility both within Peter Mac, state-based organisations and international organisations. He is a member of numerous relevant professional organisations; he reviews widely for numerous journals and grant review bodies, and is editor for three pathology journals. He sits on many pharmaceutical advisory boards for breast, lung and some gastrointestinal tumours.
Currently he has a laboratory which he established at Peter Mac focusing on prognostic and predictive markers together with the molecular pathology of cancer. Being a Clinical Pathologist, he focused on translating many of the new genomic tests including KRAS, BRAF, ALK and HER2 in colorectal, breast, lung and melanoma. He publishes widely in numerous high-impact journals, has a strong publication record in excess of 180 articles, citations in excess of 9000 (Scopus) and has an H-index of 45. He is recognised as an expert in breast and molecular pathology.